Epizyme, Inc.

NasdaqGS:EPZM Aktierapport

Börsvärde: US$247.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Epizyme Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Grant Bogle

Verkställande direktör

US$3.0m

Total ersättning

VD-lön i procent9.92%
Anställning som VD1yr
Ägande av VDn/a
Ledningens genomsnittliga anställningstid2.3yrs
Styrelsens genomsnittliga mandatperiod10.2yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Aug 09

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme press release (NASDAQ:EPZM): Q2 GAAP EPS of -$0.21. Revenue of $27.5M (+111.4% Y/Y).
Seeking Alpha • Jul 05

Epizyme Acquisition By Ipsen: CVR Value

Epizyme’s approved drug Tazverik revenue disappointed investors. Ipsen will pay $1.45 per share for Epizyme stock, plus a CVR. Any speculation at this point is about the value of the CVR. Epizyme (EPZM) graduated to being a commercial pharmaceutical company in 2020 when the FDA approved its cancer drug Tazverik. Sales never lived up to expectations, leaving Epizyme in a difficult situation in this time when raising capital for biotechnology research and development has largely dried up. Ipsen S. A. (IPSEY) has announced a plan to acquire Epizyme. The cash tender price is $1.45 per share. The stock closed on July 1 at $1.48 per share. The remaining question for Epizyme shareholders (including me), or for anyone wishing to speculate in the stock before the acquisition is completed, is the value of the CVRs (Contingent Value Rights). The focus of this article will be on possible outcomes for the CVRs. First, to inform that discussion, I will recap Epizyme history, particularly Tazverik sales figures. History highlights for Epizyme and Tazverik Epizyme was formed in 2007 to focus on epigenetic medicines. Epigenetics is a relatively new field that explores the turning on and off of genes by developmental processes, sometimes including across generations. Its lead therapy was Tazemetostat, an EZH2 inhibitor, and its first target was epithelioid sarcoma. Having been given both accelerated approval and orphan drug designation by the FDA, it reported positive Phase 2 results in October 2018. In January 2020 the FDA granted Tazverik accelerated approval for patients with epithelioid sarcoma, when it was metastatic or locally advanced and not eligible for complete resection. On January 22, 2020, the price of Epizyme stock hit $26.72 per share. That would be its all-time high. [Let that be a lesson to us all.] In December 2019 Epizyme submitted a New Drug Application to the FDA for treating a more common indication, follicular lymphoma, with Tazverik. Meanwhile, sales for the sarcoma indication got off to a slow start, largely because not that many patients fell within the label. But in June 2020 the FDA approved Tazverik for relapsed/refractory follicular lymphoma. The label narrowed the window to those patients who had an EZH2 mutation and had already received two prior systemic therapies, and those who had no satisfactory alternative treatment options. While follicular lymphoma is a relatively common cancer, third and fourth line patients with an EZH2 mutation are relatively few in number. In addition, other therapies competed in the third line market. Quarter after quarter revenue results were released, and they missed expectations that had been set by management. Here are revenue figures since Tazverik was approved: Quarter Revenue ($ millions) Q1 2020 $1.4 Q2 2020 2.5 Q3 2020 3.6 Q4 2020 8.4 Q1 2021 7.6 Q2 2021 13.0 Q3 2021 5.2 Q4 2021 11.6 Q1 2022 8.7 Table compiled by author from Seeking Alpha EPZM financials While there was an upward trend over time, we seem to be at about a $40 million annual revenue rate. Operating expenses were far larger, so cash balances kept declining. Meanwhile, at conferences, management continued to assert that Tazverik represents a multi-billion-dollar global market opportunity. In addition, there should be value in the platform and the rest of the pipeline. But with biotech out of favor this last year with investors, raising money to finance operations to get to this possible future apparently became too difficult. There was a common stock offering that raised $79.5 million in January 2022, but as the price of the stock continued to fall, the amount of dilution needed to raise funds looked like a bad proposition. At the end of Q1 2022 Epizyme still had $200 million in cash and believed its runway would last until Q3 2023. Meanwhile the stock hit a 52-week low of $0.41 per share. CVR details We know investors will get $1.45 per share. That is way better than the 52-week low of $0.41 per share, but also way below the 52-week high of $7.94 per share. That part of the offer values the company at $247 million. Each share will receive one CVR. If Tazverik achieves of $250 million in aggregate net sales (excluding in Japan and Greater China) in any period of four consecutive quarters, by 31 December 2026, the CVR will pay $0.30. While 2026 is a good time away, looking at the table above, $250 million per year seems unlikely even with successful label expansion.
Analysartikel • May 16

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

One thing we could say about the analysts on Epizyme, Inc. ( NASDAQ:EPZM ) - they aren't optimistic, having just made a...
Seeking Alpha • Nov 25

Epizyme: Taking Advantage Of Recent Sell-Off

Epizyme has been on my watch list for over a year now due to the company’s flagship product, TAZVERIK. Unfortunately, the company launched TAZVERIK right into strong COVID-19 headwinds. The company's earnings have been lackluster and the share price continues to hit new 52-week lows. Epizyme has responded with a number of actions that intend to improve adoption. I am looking to finally dip my toe in on EPZM during this recent small-cap healthcare sell-off in anticipation the company will eventually achieve their clinical and commercial goals. I discuss my bull thesis and will reveal my plans for establishing a pilot position in the near term.
Analysartikel • Sep 14

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysartikel • Aug 10

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Shareholders in Epizyme, Inc. ( NASDAQ:EPZM ) may be thrilled to learn that the analysts have just delivered a major...
Seeking Alpha • Jun 22

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Epizyme continues to advance its confirmatory studies to keep TAZVERIK on the market for treating patients with epithelioid sarcoma and follicular lymphoma. Sales of TAZVERIK were low at $6.2 million for Q1 2021, but may be due to the COVID-19 environment which hampered sales. Expanded label should improve sales over time. Two basket studies using tazemetostat are expected to be initiated in the second half of 2021; One study will target hematological malignancies and the other study will target solid tumors. A label expansion into other populations of patients with follicular lymphoma using TAZVERIK could eventually help improve sales of the drug.
Analysartikel • Jun 08

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysartikel • Feb 25

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

One thing we could say about the analysts on Epizyme, Inc. ( NASDAQ:EPZM ) - they aren't optimistic, having just made a...
Analysartikel • Jan 16

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysartikel • Dec 12

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

Analys av ersättningar till VD

Hur har Grant Bogle:s ersättning förändrats jämfört med Epizyme:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$236m

Dec 31 2021US$3mUS$299k

-US$251m

Sep 30 2021n/an/a

-US$267m

Jun 30 2021n/an/a

-US$257m

Mar 31 2021n/an/a

-US$251m

Dec 31 2020US$196kn/a

-US$232m

Sep 30 2020n/an/a

-US$222m

Jun 30 2020n/an/a

-US$202m

Mar 31 2020n/an/a

-US$192m

Dec 31 2019US$309kn/a

-US$173m

Ersättning vs marknad: Grant s total kompensation ($USD 3.01M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 1.66M ).

Ersättning vs inkomst: Ersättningen för Grant har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

Grant Bogle (64 yo)

1yr
Anställning
US$3,011,807
Kompensation

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Grant Bogle
President1yrUS$3.01minga uppgifter
Jeffery Kutok
Chief Scientific Officer2.3yrsUS$2.86m0.0080%
$ 19.9k
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datainga uppgifteringa uppgifter
Jerald Korn
Chief Operating Officerless than a yearinga uppgifteringa uppgifter
Joseph Beaulieu
Senior VP4.1yrsinga uppgifter0.0058%
$ 14.3k
Craig West
Vice President of Investor Relationsno datainga uppgifteringa uppgifter
John Weidenbruch
Senior VPno datainga uppgifteringa uppgifter
Tanja Weber
Chief Business Officer3.6yrsinga uppgifteringa uppgifter
Mark De Rosch
Chief Regulatory Officer2.8yrsinga uppgifteringa uppgifter
Rebecca Mehrwerth
Senior VP & Head of Commercialless than a yearinga uppgifteringa uppgifter
Christoph Diefenbach
Laboratory Manager of Research & Developmentno datainga uppgifteringa uppgifter
2.3yrs
Genomsnittlig anställningstid
56.5yo
Genomsnittlig ålder

Erfaren ledning: EPZM s ledningsgrupp anses vara erfaren ( 2.3 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Grant Bogle
President2.9yrsUS$3.01minga uppgifter
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datainga uppgifteringa uppgifter
George Daley
Member of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
David Mott
Independent Chairman12.7yrsUS$370.00k0.19%
$ 474.0k
Carl Goldfischer
Independent Director12.9yrsUS$350.00k0.0030%
$ 7.4k
Christopher Walsh
Member of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Kenneth Bate
Independent Director7.7yrsUS$330.94k0%
$ 0
Bruce Chabner
Member of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Ronald Evans
Member of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Joel Huff
Member of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Steven Henikoff
Member of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
10.2yrs
Genomsnittlig anställningstid
68yo
Genomsnittlig ålder

Erfaren styrelse: EPZM s styrelse är rutinerade och erfaren ( 10.2 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2022/08/12 07:54
Aktiekurs vid dagens slut2022/08/11 00:00
Intäkter2022/06/30
Årlig intjäning2021/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Epizyme, Inc. bevakas av 14 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Mohit BansalCitigroup Inc
Michael KingCitizens JMP Securities, LLC
Andrew FeinH.C. Wainwright & Co.